Zeo ScientifiX, Inc. (ZEOX)
OTC Markets OTCQB
Price as at 1 Oct 2026, 04:10 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Zeo ScientifiX, Inc. trades at $1.24. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, osteoarthritis,and traumatic brain injury. The company also provides Patient Pure X, an autologous biologic, that helps reduce inflammation and promote tissue healing and regeneration. In addition, it develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; ZEO GROWX, ZEO HAIR GROW, and ZEO GROW BOOST, a serum comprised of hair growth stimulants for follicle stimulation. The company has a strategic collaboration with Regen Therapy Limited for the development of biologic therapeutics. The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in February 2024. Zeo ScientifiX, Inc. was incorporated in 2011 and is based in Davie, Florida.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its ZEOX data?
Fundamentals for ZEOX come from company filings and exchange data, as listed on OTC Markets OTCQB; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 04:10 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ZEOX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.